.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, taking up the top scientific research area at Sanofi.Quigley will definitely begin Sept. 30 as the French Big Pharma's chief scientific officer and worldwide chief of research, Sanofi informed Brutal Biotech in an emailed claim.Quigley is substituting Frank Nestle, M.D., who left Sanofi this springtime amidst a global overhaul of the company's R&D system. Nestle, who devoted eight years with the pharma, dove over to Deerfield Management, where he currently serves as a partner on the therapeutics team as well as chief executive officer of the organization's healing discovery and growth procedures.
Quigley will sign up with Sanofi coming from a San Francisco-based biotech that remains in stealth, depending on to his LinkedIn profile. He is actually presently specified as the company's founder, head of state as well as chief executive officer.Since August 2021, Quigley has actually acted as a project partner at SV Wellness Investors, a medical care fund manager with existing financial investments in biotechs such as BioAge, Cerevance, Dualitas Rehabs and also Nimbus Rehabs, to name a few. Quigley formerly held the leading location at Dualitas, a biotech that stays in stealth, depending on to STAT.The prospective Sanofi leader additionally previously helmed Therini Bio, an immunotherapy biotech working to develop treatments for neurodegenerative diseases steered through vascular problems.Just before spending the final couple of years in biotech, Quigley possesses an even longer track record in Large Pharma, very most just recently functioning as Gilead's elderly vice president of analysis the field of biology until the summertime of 2021. Just before that, he appeared greater than 4 years throughout different leadership duties at Bristol Myers Squibb and also served as a clinical supervisor at Johnson & Johnson's Janssen upper arm just before that.Sanofi said Quigley's objective in his new task would be actually to "optimize our probability of excellence through superior partnerships throughout our organization and also past, bringing best-in-class innovation along with establishing as well as sourcing brand-new industry-leading talent along with a dedication to variety," depending on to an internal memo secured through STAT.